Biogelx is helping people working in translational science, drug discovery and tissue engineering by Â“making in vitro cell cultures more in vivoÂ”. They do this through manufacturing and supplying 3D cell cultures that can be tuned to specific tissues and synthetic bioinks that are reproducible and easy to handle.
- (24.Mar.2020) Biogelx Announce Alison Clayton as New CEO
- (31.Jan.2020) CEO Mitch Scanlan is Retiring
- (12.Nov.2019) Biogelx is Pleased to Announce Strategic Collaboration with Regemat3D
- (30.Aug.2019) New Generation RGD Functionalised Bioink from Biogelx